Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors

  title={Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors},
  author={Michael H. Nelson and Christian R. Dolder},
  journal={Annals of Pharmacotherapy},
  pages={261 - 269}
  • Michael H. Nelson, Christian R. Dolder
  • Published 2006
  • Medicine
  • Annals of Pharmacotherapy
  • Objective: To review the pharmacology, pharmacokinetics, clinical trials, adverse effects, and drug interactions of lapatinib. Data Sources: A PubMed search was conducted (1966–August 2005) using the following terms: lapatinib, GW572016, and dual tyrosine kinase inhibitor. Additional information sources included meeting abstracts, clinical trial data, and bibliographies from articles identified through PubMed. Study Selection and Data Extraction: Preclinical and clinical trials that evaluated… CONTINUE READING
    153 Citations

    Paper Mentions

    The purpose of this study is to characterize the microscopic findings of skin rash associated with the use of chemotherapeutic anticancer agents known as epidermal growth factor… Expand
    ConditionsSkin Rash
    Lapatinib in breast cancer.
    • 73
    • PDF
    Pharmacology of epidermal growth factor inhibitors.
    • 28
    Lapatinib: current status and future directions in breast cancer.
    • 150
    • PDF
    Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments
    • 129
    • 16


    Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
    • N. Spector, W. Xia, +17 authors S. Bacus
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2005
    • 349
    Small molecule tyrosine kinase inhibitors in pancreatic cancer
    • 17
    • PDF
    Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.
    • 117